SINGAPORE--(BUSINESS WIRE)--SCIEX, a global leader in life science analytical technologies, and the Bioprocessing Technology Institute (BTI), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR) with expertise in bioprocess science and engineering, today announced a collaboration to advance research and development in the area of biologics in Singapore.
Biologics refer to a new class of therapeutics, including monoclonal antibodies and antibody drug conjugates, which are increasingly being used for the treatment and prevention of human diseases. Unlike conventional drugs that are chemically synthesized, biologics are produced using cell cultures and represent an increasing growth area due to its potential to treat a range of conditions with no treatments available presently. While biologics hold great therapeutic benefits, much effort and cost is needed to purify these drugs, to eliminate residual components of the host cell system used in manufacturing. These components, or host cell proteins, may elicit unpredictable immune responses in patients or compromise the stability of the product.
Biologics refer to a new class of therapeutics, including monoclonal antibodies and antibody drug conjugates, which are increasingly being used for the treatment and prevention of human diseases. Unlike conventional drugs that are chemically synthesized, biologics are produced using cell cultures and represent an increasing growth area due to its potential to treat a range of conditions with no treatments available presently. While biologics hold great therapeutic benefits, much effort and cost is needed to purify these drugs, to eliminate residual components of the host cell system used in manufacturing. These components, or host cell proteins, may elicit unpredictable immune responses in patients or compromise the stability of the product.
